Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
- Ovid Therapeutics reported a quarterly loss of $0.17 per share, beating estimates by 26.09%. - Revenue for Ovid increased to $0.15 million, exceeding the Zacks Consensus Estimate by 40.95%. - Ovid's stock has lost 6.2% year-to-date, underperforming the S&P 500. - Management's commentary on earnings call will impact stock's immediate movement. - Estimate revisions for Ovid Therapeutics are currently mixed. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
- Ovid Therapeutics reported a quarterly loss of $0.17 per share, beating estimates by 26.09%.
- Revenue for Ovid increased to $0.15 million, exceeding the Zacks Consensus Estimate by 40.95%.
- Ovid's stock has lost 6.2% year-to-date, underperforming the S&P 500.
- Management's commentary on earnings call will impact stock's immediate movement.
- Estimate revisions for Ovid Therapeutics are currently mixed.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.